Clinical Study on General lmmunotherapy of Hepatocellular Carcinoma

In the present study,67 cases of hepatocellular carcinoma(HCC)were treated withimmunotherapy or immunochernotherapy.The results indicated that natural killer cell(NK)andantibody-dependent cytotoxicity cell(ADCC)activities and lymphocyte transformation rate(LTR)were significantly improved in vivo after treatment.The NK activity in tumor tissue,which showed aheavy immunosuppression,could also be enhanced and recovered to normal level after treatment withlymphokine mixture and 5-fluorouracil(5-FU).Immunity of host with postoperativeimmunochemotherapy was rapidly improved and recovery vate was high.The survival time in thesecases of unresectable tumors was obviously prolonged when a general immunotherapy was used.Immunochemotherapy can impr(?)ve immunity and inhibit selectively Ts cells as well as kill directly thetremor cells;therefore,it can play an important role in the treatment of hepatocellular carcinomaand in the prevention of its recurrence after operation.     

用优球蛋白作免疫原制备抗人C1q抗体

本文介绍一种不用纯的C1q抗原制备抗人补体C1q抗体的简便方法。作为免疫原的富含C1q的优球蛋白组分是通过0.026 M EGTA 缓冲液透析血清,尔后在0.6％琼脂糖凝胶(pH8.6)中电泳等二步分离方法而获得。此免疫原产生的抗血清中的杂抗体,用已去掉C1q的血清经戊二醛交联而制成的免疫吸附剂除去。通过此法制得的特异性抗C1q抗体,用免疫电泳(IEP)方法测试,它与人全血清或纯的C1q反应仅在慢γ-区出现一条沉淀线,用双向免疫扩散(DID)法试验,它与纯C1q反应形成一条沉淀线且与标准抗C1q抗体的沉淀线呈现完全融合的反应,此外它能够凝集EAC1q细胞而不凝集EA细胞。 这些结果表明此最终产品是抗人C1q的单价特异性抗体制品。     

原发性肝癌的免疫化学治疗

应用混合淋巴因子、低剂量5-氟脲嘧啶(5-Fu)治疗67例原发性肝细胞癌(HCC)。结果表明,免疫综合治疗能增强宿主NK、ADCC效应和淋巴细胞转化率。混合淋巴因子附加5-Fu在体外能使癌组织内处于严重抑制状态的NK活性恢复。肝癌切除术后应用免疫化疗宿主免疫功能恢复快,恢复率高,单纯给于免疫综合治疗的病例,其生存期亦明显延长。免疫化疗具有增强机体免疫力,解除免疫抑制和直接抑制肿瘤生长、扩散等多重抗癌功能,在肝癌治疗中,尤其在术后抗复发治疗上有重要价值。     

原发性肝癌免疫化学治疗的临床初步观察

干扰素(IFN)和白细胞介素2(IL-2)有明显的免疫调节活性和抗癌功能,同时附加低剂量化疗药物则抗癌作用明显增强,有关这些治疗研究,迄今报道不多。本研究应用混合淋巴因子,低剂量5-氟脲嘧啶(5-Fu)对67例原发性肝细胞癌(HCC)进行了治疗观察。结果表明,免疫综合治疗能增     

应用人外周血淋巴细胞、单核细胞和巨噬细胞培养物联合产生γ干扰素

本文报导了用有丝分裂原分别刺激人外周血单个核白细胞(Mononuclear Cells)、单核细胞、巨噬细胞(由单核细胞培养7天获得)、淋巴细胞加自体单核细胞或巨噬细胞后,γ干扰素产生的情况,其结果如下。